Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Amortizatization of Intangibles: 2020-2024

Historic Amortizatization of Intangibles for Fulcrum Therapeutics (FULC) over the last 5 years, with Dec 2024 value amounting to $4.4 million.

  • Fulcrum Therapeutics' Amortizatization of Intangibles fell 49.13% to $586,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $3.5 million, marking a year-over-year decrease of 26.39%. This contributed to the annual value of $4.4 million for FY2024, which is 26.69% down from last year.
  • Per Fulcrum Therapeutics' latest filing, its Amortizatization of Intangibles stood at $4.4 million for FY2024, which was down 26.69% from $6.0 million recorded in FY2023.
  • Fulcrum Therapeutics' Amortizatization of Intangibles' 5-year high stood at $6.0 million during FY2023, with a 5-year trough of -$673,000 in FY2021.
  • For the 3-year period, Fulcrum Therapeutics' Amortizatization of Intangibles averaged around $3.4 million, with its median value being $4.4 million (2024).
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first plummeted by 1,089.71% in 2021, then skyrocketed by 4,041.45% in 2023.
  • Fulcrum Therapeutics' Amortizatization of Intangibles (Yearly) stood at $68,000 in 2020, then slumped by 1,089.71% to -$673,000 in 2021, then soared by 77.41% to -$152,000 in 2022, then skyrocketed by 4,041.45% to $6.0 million in 2023, then declined by 26.69% to $4.4 million in 2024.